Rifabutin (BioVersys)

利福布汀 (BioVersys)

Report date: 2026/05/13 20:02:10
QIDP

Base Information

Drug NameRifabutin (BioVersys)
Drug Alias NameBV-100Bv100
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBacterial DNA-directed RNA polymerase inhibitors
TargetsBacterial DNA-directed RNA polymerase
Therapy Area/IndicationsHospital-acquired pneumoniaAcinetobacter Baumannii InfectionsRenal Insufficiency +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryHungaryGeorgiaAustria +[5] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBioVersys AG
China Registration ClassN/A

Develop Information

Active CompaniesGuangZhou BioVersys Pharmaceutical Co LtdIstituto Biochimico Italiano G. Lorenzini SpaBioVersys AG +[4] 
Inactive CompaniesN/A
Active IndicationsHospital-acquired pneumoniaAcinetobacter Baumannii InfectionsRenal Insufficiency +[7] 
Inactive IndicationsInfections

Other Information

ATC CodeN/A
Related LinksN/A